• Member News

Synpromics named among the top 50 fastest growing technology companies in the UK

Synpromics 12th in the Deloitte UK Technology Fast 50. Synpromics is delighted to announce that it has been ranked 12th in the Deloitte ‘UK Technology Fast 50’ at the annual awards ceremony in London last night.

Expedeon AG signs supply and license agreement with Quanterix Corporation for access to proprietary immunoassay technology

Expedeon’s proprietary immunoassay technology to be incorporated into Quanterix’ Simoa Planar Immunoassay products

Research Showcase launches new collaboration to accelerate translation of more predictive research models in drug discovery

Medicines Discovery Catapult and the National Centre for the Replacement, Refinement & Reduction of Animals in Research (NC3Rs) announce strategic collaboration to accelerate the translation of more predictive in vitro research models into new products and services

New collaboration will advance human-based drug evaluation

Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) at the University of Liverpool announce strategic collaboration to develop next generation human cell models

Enesi Pharma and Sementis sign R&D Collaboration focused on Needle-free Solid Dose Vaccines for Peanut Allergy and chikungunya/Zika Infection

Oxford, UK and Melbourne, Australia – 5 November 2018. Enesi Pharma and Sementi, announce they have entered into a collaborative agreement. The collaboration is focused on the development and evaluation of solid dose versions of Sementis’ lead peanut hypoallergy vaccine and their single vectored chikungunya/Zika vaccine candidates for administration via Enesi Pharma’s ImplaVax® technology

New lab facility for life science companies to open on Newcastle Helix

A brand-new lab facility is soon to be opening within the heart of Newcastle’s £350m urban development scheme - Newcastle Helix.

Medherant announces positive Phase I results for its first transdermal drug delivery patch

Medherant, a developer of innovative transdermal drug delivery treatments for pain and CNS diseases, has successfully completed two Phase I studies with its novel Ibuprofen TEPI® Patch.

Leading AI-driven drug discovery company Exscientia expands to The Oxford Science Park

Oxford, UK, 1 November 2018 - In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK's leading parks for science and technology companies.

Arecor - PATENT PORTFOLIO UPDATE

Arecor successfully defends a key European patent in opposition proceedings on the subject of mitigation of aggregation of therapeutic proteins during storage

Cobra Biologics and the University of Leeds Collaborate in BioProNET Funded Project

£100K grant will fund proof-of-concept studies to optimise bioprocessing of gene therapy vectors using hydrodynamic fluid flow fields